Profounda receives FDA Orphan Drug Designation for miltefosine for treating Primary Amebic Meningoencephalitis (PAM)
Profounda, Inc. announced Friday that it has received, the US Food and Drug Administration’s (FDA) Orphan Drug Designation for the treatment of Primary Amebic Meningoencephalitis (PAM) with miltefosine. More...
Janssen Therapeutic’s ‘Sirturo’ receives FDA approval for treatment of multi-drug resistant pulmonary tuberculosis
This is an anteroposterior (AP) x-ray of a patient’s chest, who was diagnosed with bilateral pulmonary tuberculosis. Image/CDC In a follow-up to a Dec. 1 story, Janssen Therapeutics has announced the U.S. More...
Orphan drug, Juxtapid gets FDA approval for treating HoFH
The US Food and Drug Administration announced the approval of Juxtapid (lomitapide), a new orphan drug used to reduce cholesterol in patients with the rare disorder, homozygous familial hypercholesterolemia (HoFH), More...
